Diagnamed Holdings (FRA:D75) Research & Development: €-0.05 Mil (TTM As of Mar. 2026)


What is Diagnamed Holdings Research & Development?

Diagnamed Holdings FRA:D75 Research & Development is €-0.05 Mil as of Mar. 2026. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Diagnamed Holdings's Research & Development for the three months ended in Mar. 2026 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.05 Mil.

Diagnamed Holdings  (FRA:D75) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Diagnamed Holdings Research & Development Related Terms

Diagnamed Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Diagnamed Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diagnamed Holdings Research & Development Chart

Diagnamed Holdings Annual Data
Trend Sep21 Sep22 Sep23 Sep24 Sep25
Research & Development
0.14 0.43 0.24 0.16 0.03

Diagnamed Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.02 -0.06 0.00 0.00

Diagnamed Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €-0.05 Mil mean?
Diagnamed Holdings (FRA:D75) has a Research & Development of €-0.05 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Diagnamed Holdings and its competitors.
Is Diagnamed Holdings' Research & Development too high?
Diagnamed Holdings' current Research & Development is €-0.05 Mil.
How does Diagnamed Holdings' Research & Development compare to VEEV and BTSG?
Diagnamed Holdings' Research & Development of €-0.05 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Diagnamed Holdings and its competitors. Diagnamed Holdings's current Research & Development is €-0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnamed Holdings stock overvalued right now?
Diagnamed Holdings (FRA:D75) has a current Research & Development of €-0.05 Mil. The current Research & Development is €-0.05 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Diagnamed Holdings (FRA:D75), the current Research & Development is €-0.05 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Diagnamed Holdings Business Description

Other Exchanges DGNMF:USADMED:Canada
Address 82 Richmond Street East, Toronto, ON, CAN, M5C 1P1
Diagnamed Holdings Corp is engaged in developing a platform of software-based prescription digital therapeutic products (PDT Products) with the potential to improve early detection of neurological disorders, overall patient health and lower healthcare costs. Its products include, CERVAI which is a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It is also investigating other technological applications such as BrainAge and BrainTremor.